Alyssum Therapeutics Inc Press Releases

• Published on January 8, 2025 - 14:00 GMT

  Alyssum Therapeutics, a clinical stage immunology company, expands Series A with participation from Femhealth Ventures

  • Will fund clinical trials with a first in class, clinical stage CMTR2 inhibitor that activates a B cell immune response against tumors CAMBRIDGE, MA, UNITED STATES, January 8, 2025 /⁨EINPresswire.com⁩/ -- Alyssum Therapeutics, which recently came out of …

  Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
• Published on October 23, 2024 - 16:00 GMT

  Alyssum Therapeutics closes Series A and emerges from stealth mode as a clinical stage B cell immunology company

  • A clinical stage B cell immunotherapy company for cancer and autoimmune diseases • Alyssum team has collectively developed over twenty clinical therapeutics CAMBRIDGE, MA, UNITED STATES, October 23, 2024 /⁨EINPresswire.com⁩/ -- Alyssum Therapeutics, …

  Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...